Search

Jay F Rappaport

from Mandeville, LA
Age ~68
Get Report
Also known as:
Jay Dr Rappaport, Jay Franklin Rappaport, Jay L Rappaport, Jay S Rappaport, Susan L Rappaport, Susan G Rappaport, Jay Rapport, Jay R, Jay I, Jack Rappaport
Related to:
Robert L Cole, 78Eric Cole, 50Larry Quinzani, 70Cynthia Cole, 76Joseph R Bonfig, 48
Connected to:
Alfred Rappaport, 114Austin Rappaport, 40Denise Rappaport, 82Harold B Rappaport, 69Harris E Rappaport, 59Jan L Rappaport, 91Joanne Rappaport, 71Larry B Rappaport, 76Linda L Rappaport, 78Lindsey Rappaport, 42

Jay Rappaport Phones & Addresses

  • Mandeville, LA
  • 1944 Glendon Ave APT 207, Los Angeles, CA 90025
  • Madisonville, LA
  • 522 Rhode Island Ave, Somers Point, NJ 08244
  • Cherry Hill, NJ
  • Wynnewood, PA
  • Bala Cynwyd, PA
  • New York, NY
  • Montgomery, PA
  • Atlantic Hl, NJ

Work

Position: Building and Grounds Cleaning and Maintenance Occupations

Specialities

Automobile Product Liability • General Litigation and Transactions • Medical Malpractice Litigation • Product Liability • Toxic Tort Litigation

Professional Records

Lawyers & Attorneys

Jay Rappaport Photo 1

Jay Rappaport - Lawyer

View page
Office:
Aaronson Rappaport Feinstein & Deutsch, LLP
Specialties:
Automobile Product Liability
General Litigation and Transactions
Medical Malpractice Litigation
Product Liability
Toxic Tort Litigation
ISLN:
901770774
Admitted:
1974
University:
George Washington University, B.A., 1970
Law School:
New York Law School, J.D., 1973

Resumes

Resumes

Jay Rappaport Photo 2

Chief Executive Officer And Founder

View page
Location:
12016 Aol Way, Sterling, VA 20166
Industry:
Investment Management
Work:
Legacy Investing
Chief Executive Officer and Founder
Addthis Mar 2007 - May 2009
President and Chief Operations Officer
Vonage 2005 - 2006
President
Centurion Investments 2005 - 2006
Co-Founder and Managing Member
Aol 2001 - 2002
Chief Operating Officer
Education:
University of California, Los Angeles - School of Law 1987 - 1990
Doctor of Jurisprudence, Doctorates Washington University In St. Louis - Olin Business School 1983 - 1987
Bachelors, Bachelor of Science, Business, Accounting, Finance University of California
Washington University In St. Louis
Skills:
Product Management
Digital Media
Product Marketing
Web 2.0
Jay Rappaport Photo 3

Jay Rappaport

View page

Publications

Us Patents

Blood Monocyte Cd163 Expression As A Biomarker In Hiv-1 Infection And Neuroaids

View page
US Patent:
8273538, Sep 25, 2012
Filed:
May 25, 2007
Appl. No.:
12/301796
Inventors:
Jay Rappaport - Somers Point NJ, US
Tracy Fischer-Smith - Horsham PA, US
Assignee:
Temple University of the Commonwealth System of Higher Education - Philadelphia PA
International Classification:
C12Q 1/70
C12Q 1/68
G01N 33/53
G01N 33/567
US Classification:
435 71, 435 61, 435 72, 435 721, 435 5
Abstract:
The invention provides a method for detecting CD163+/CD16+ cell population in peripheral blood mononuclear cells in a biological sample from a subject infected with HIV-1 which comprises contacting the biological sample with an anti-CD163 antibody, so that levels of CD163+/CD16+ peripheral blood mononuclear cells in the biological sample can be quantified. The method of the present invention is particularly useful for monitoring the course of HIV-1 infection and/or HIV Encephalopathy.

Mutated Hiv Tat

View page
US Patent:
20040005330, Jan 8, 2004
Filed:
Dec 5, 2002
Appl. No.:
10/310740
Inventors:
Jay Rappaport - Bala Cynwyd PA, US
Michel Klein - La Tour de Salvagny, FR
Jean Zagury - Paris, FR
International Classification:
A61K039/21
C07H021/04
C07K014/16
C12P021/02
C12N005/06
C12N015/867
US Classification:
424/188100, 530/350000, 435/069300, 435/320100, 435/325000, 536/023720
Abstract:
The present invention provides a Tat protein wherein all the cysteine residues of the cysteine-rich domain have been replaced with another amino acid, preferably with serine, nucleic acids encoding it, and methods of using it to elicit a humoral and cellular immune responses in a mammal. The Tat protein of the invention is therefore useful, inter alia, for prophylactic and/or therapeutic anti-HIV use as well as raising anti-native Tat antibodies in mammals.

Treatment Of Hiv-1 By Modulation Of Vpr Activation Of The M-Csf Promoter

View page
US Patent:
20090117155, May 7, 2009
Filed:
May 24, 2007
Appl. No.:
12/302189
Inventors:
Jay Rappaport - Somers Point NJ, US
Valerie Haine - Namur, BE
Tracy Fischer-Smith - Horsham PA, US
International Classification:
A61K 39/12
C12N 15/11
C12N 15/00
C12N 5/06
C12N 1/21
A61K 31/575
C12Q 1/68
C12Q 1/70
C12Q 1/66
A61K 31/7105
US Classification:
4242081, 536 232, 4353201, 435325, 4352523, 435 6, 435 5, 435 8, 514 44, 514178
Abstract:
Macrophage colony-stimulating factor (M-CSF) is important for human immunodeficiency virus-type 1 (HIV-1) infection, replication and survival of infected cells. The mechanism(s) by which HIV-1 infection increases M-CSF production are, however, poorly understood. Here, we report that HIV-1 Vpr enhances M-CSF promoter activity and production in primary human monocytes and macrophages. Vpr activates M-CSF transcription through four C/EBP beta binding sites present within the M-CSF promoter, possibly through increased phosphorylation of C/EBP beta. RU486 (mifepristone) blocked Vpr-mediated up-regulation of M-CSF, suggesting that Vpr activates M-CSF promoter activity via the glucocorticoid pathway. The invention provides new avenues for therapeutic interventions in HIV-1 infection and other diseases involving M-CSF dysregulation (including malignancy, osteoporosis, autoimmune disorders, arthritis, and obesity) using glucocorticoid antagonists and modulators of C/EBP beta activity.

Detection Of Hiv-1-Associated Neurocognitive Disorders

View page
US Patent:
20170176408, Jun 22, 2017
Filed:
Mar 24, 2015
Appl. No.:
15/129353
Inventors:
- Philadelphia PA, US
- Baltimore MD, US
Kamel Khalili - Bala Cynwyd PA, US
Jay Rappaport - Somers Point NJ, US
Norman J. Haughey - Baltimore MD, US
Ned Sacktor - Baltimore MD, US
International Classification:
G01N 33/487
G01N 30/88
Abstract:
Provided is a method of detecting mild neurocognitive disturbance (MNCD) or HIV associated dementia (HAD) in a patient comprising detecting the level of acetyl spermine and/or acetyl spermidine from a cerebrospinal fluid test sample of the patient; and comparing the level of acetyl spermine and/or acetyl spermidine in the test sample to the level of the acetyl spermine and/or acetyl spermidine in a cerebrospinal fluid control sample or to a control value for lack of neurocognitive impairment, MNCD or HAD; wherein an elevated level of acetyl spermine and/or acetyl spermidine in the test sample as compared to the level in the control sample or a control value for lack of neurocognitive impairment, or a level of acetyl spermine and/or acetyl spermidine that is similar to that of a control value for MNCD or HAD, indicates that the patient suffers from MNCD or HAD. Also provided are methods for measuring the progression of an HIV-1-associated neurocognitive disorder, as well as methods for staging such a disorder.
Control profile
Jay F Rappaport from Mandeville, LA, age ~68 Get Report